

# Barbara Ensoli

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2655887/publications.pdf>

Version: 2024-02-01

230  
papers

14,559  
citations

20817

60  
h-index

22832

112  
g-index

232  
all docs

232  
docs citations

232  
times ranked

8746  
citing authors

#	ARTICLE	IF	CITATIONS
1	Kaposi's Sarcoma Lesion Progression in BKV-Tat Transgenic Mice Is Increased by Inflammatory Cytokines and Blocked by Treatment with Anti-Tat Antibodies. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2081.	4.1	0
2	Anti-Tat immunity defines CD4+ T-cell dynamics in people living with HIV on long-term cART.. <i>EBioMedicine</i> , 2021, 66, 103306.	6.1	11
3	New insights into pathogenesis point to HIV-1 Tat as a key vaccine target. <i>Archives of Virology</i> , 2021, 166, 2955-2974.	2.1	6
4	HIV-1 Tat Protein Enters Dysfunctional Endothelial Cells via Integrins and Renders Them Permissive to Virus Replication. <i>International Journal of Molecular Sciences</i> , 2021, 22, 317.	4.1	12
5	HIV Protease Inhibitors Block HPV16-Induced Murine Cervical Carcinoma and Promote Vessel Normalization in Association with MMP-9 Inhibition and TIMP-3 Induction. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 2476-2489.	4.1	5
6	Global and regional epidemiology of HIV-1 recombinants in 1990-2015: a systematic review and global survey. <i>Lancet HIV</i> , 2020, 7, e772-e781.	4.7	51
7	The Tat Protein of HIV-1 Prevents the Loss of HSV-Specific Memory Adaptive Responses and Favors the Control of Viral Reactivation. <i>Vaccines</i> , 2020, 8, 274.	4.4	3
8	High HIV-1 diversity in immigrants resident in Italy (2008-2017). <i>Scientific Reports</i> , 2020, 10, 3226.	3.3	8
9	HIV therapeutic vaccines aimed at intensifying combination antiretroviral therapy. <i>Expert Review of Vaccines</i> , 2020, 19, 71-84.	4.4	12
10	Anti-Tat Immunity in HIV-1 Infection: Effects of Naturally Occurring and Vaccine-Induced Antibodies Against Tat on the Course of the Disease. <i>Vaccines</i> , 2019, 7, 99.	4.4	14
11	Continued Decay of HIV Proviral DNA Upon Vaccination With HIV-1 Tat of Subjects on Long-Term ART: An 8-Year Follow-Up Study. <i>Frontiers in Immunology</i> , 2019, 10, 233.	4.8	23
12	Global and regional molecular epidemiology of HIV-1, 1990-2015: a systematic review, global survey, and trend analysis. <i>Lancet Infectious Diseases</i> , 2019, 19, 143-155.	9.1	255
13	The HIV-1 Tat protein affects human CD4+ T-cell programming and activation, and favors the differentiation of naive CD4+ T cells. <i>Aids</i> , 2018, 32, 575-581.	2.2	33
14	The Impact of Human Papilloma Viruses, Matrix Metallo-Proteinases and HIV Protease Inhibitors on the Onset and Progression of Uterine Cervix Epithelial Tumors: A Review of Preclinical and Clinical Studies. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1418.	4.1	15
15	Genetic diversity in the env V1-V2 region of proviral quasispecies from long-term controller MHC-typed cynomolgus macaques infected with SHIV SF162P4cy. <i>Journal of General Virology</i> , 2018, 99, 1717-1728.	2.9	3
16	Inhibition of MMP-9 expression by ritonavir or saquinavir is associated with inactivation of the AKT/Fra-1 pathway in cervical intraepithelial neoplasia cells. <i>Oncology Letters</i> , 2017, 13, 2903-2908.	1.8	8
17	ART intensification by the HIV-1 Tat B clade vaccine: progress to phase III efficacy studies. <i>Expert Review of Vaccines</i> , 2017, 17, 1-12.	4.4	4
18	Old and New Concepts and Strategies in HIV Vaccinology: A Report from a Workshop held in Rome on 17 June 2016. <i>Journal of AIDS &amp; Clinical Research</i> , 2016, 7, .	0.5	4

#	ARTICLE	IF	CITATIONS
19	Association between different anti-Tat antibody isotypes and HIV disease progression: data from an African cohort. <i>BMC Infectious Diseases</i> , 2016, 16, 344.	2.9	18
20	HIV-1 Tat protein vaccination in mice infected with <i>Mycobacterium tuberculosis</i> is safe, immunogenic and reduces bacterial lung pathology. <i>BMC Infectious Diseases</i> , 2016, 16, 442.	2.9	8
21	Systemic immunodominant CD8 responses with an effector-like phenotype are induced by intravaginal immunization with attenuated HSV vectors expressing HIV Tat and mediate protection against HSV infection. <i>Vaccine</i> , 2016, 34, 2216-2224.	3.8	14
22	Entrance of the Tat protein of HIV-1 into human uterine cervical carcinoma cells causes upregulation of HPV-E6 expression and a decrease in p53 protein levels. <i>Oncology Letters</i> , 2016, 12, 2389-2394.	1.8	29
23	Correlates of infection and molecular characterization of blood-borne HIV, HCV, and HBV infections in HIV-1 infected inmates in Italy. <i>Medicine (United States)</i> , 2016, 95, e5257.	1.0	10
24	HIV-Tat immunization induces cross-clade neutralizing antibodies and CD4+ T cell increases in antiretroviral-treated South African volunteers: a randomized phase II clinical trial. <i>Retrovirology</i> , 2016, 13, 34.	2.0	33
25	Approaches to preventative and therapeutic HIV vaccines. <i>Current Opinion in Virology</i> , 2016, 17, 104-109.	5.4	72
26	HIV-1 Tat immunization restores immune homeostasis and attacks the HAART-resistant blood HIV DNA: results of a randomized phase II exploratory clinical trial. <i>Retrovirology</i> , 2015, 12, 33.	2.0	55
27	Effects of different routes of administration on the immunogenicity of the Tat protein and a Tat-derived peptide. <i>Human Vaccines and Immunotherapeutics</i> , 2015, 11, 1489-1493.	3.3	4
28	Development of a novel AIDS vaccine: the HIV-1 transactivator of transcription protein vaccine. <i>Expert Opinion on Biological Therapy</i> , 2015, 15, 13-29.	3.1	19
29	Building up a collaborative network for the surveillance of HIV genetic diversity in Italy. A pilot study. <i>Annali Dell'Istituto Superiore Di Sanita</i> , 2015, 51, 321-6.	0.4	0
30	Effect of MHC Haplotype on Immune Response upon Experimental SHIVSF162P4cy Infection of Mauritian <i>Cynomolgus</i> Macaques. <i>PLoS ONE</i> , 2014, 9, e93235.	2.5	10
31	Molecular Characterization of HIV-1 Subtype C gp-120 Regions Potentially Involved in Virus Adaptive Mechanisms. <i>PLoS ONE</i> , 2014, 9, e95183.	2.5	3
32	Induction of Antibodies and T Cell Responses by a Recombinant Influenza Virus Carrying an HIV-1 Tat <sup>51-59</sup> Protein in Mice. <i>BioMed Research International</i> , 2014, 2014, 1-10.	1.9	2
33	HIV-1 Tat affects the programming and functionality of human CD8+ T cells by modulating the expression of T-box transcription factors. <i>Aids</i> , 2014, 28, 1729-1738.	2.2	39
34	Surface-bound Tat inhibits antigen-specific CD8+ T-cell activation in an integrin-dependent manner. <i>Aids</i> , 2014, 28, 2189-2200.	2.2	24
35	Challenges in HIV Vaccine Research for Treatment and Prevention. <i>Frontiers in Immunology</i> , 2014, 5, 417.	4.8	52
36	The presence of anti-Tat antibodies in HIV-infected individuals is associated with containment of CD4+T-cell decay and viral load, and with delay of disease progression: results of a 3-year cohort study. <i>Retrovirology</i> , 2014, 11, 49.	2.0	48

#	ARTICLE	IF	CITATIONS
37	The HIV protease inhibitor indinavir down-regulates the expression of the pro-angiogenic MT1-MMP by human endothelial cells. <i>Angiogenesis</i> , 2014, 17, 831-838.	7.2	13
38	An Attenuated Herpes Simplex Virus Type 1 (HSV1) Encoding the HIV-1 Tat Protein Protects Mice from a Deadly Mucosal HSV1 Challenge. <i>PLoS ONE</i> , 2014, 9, e100844.	2.5	15
39	Biocompatible Anionic Polymeric Microspheres as Priming Delivery System for Effective HIV/AIDS Tat-Based Vaccines. <i>PLoS ONE</i> , 2014, 9, e111360.	2.5	4
40	ATL. <i>International Journal of Gynecological Cancer</i> , 2013, 23, 1663-1669.	2.5	24
41	The HIV-1 Tat Protein Induces the Activation of CD8+ T Cells and Affects In Vivo the Magnitude and Kinetics of Antiviral Responses. <i>PLoS ONE</i> , 2013, 8, e77746.	2.5	35
42	Ritonavir or saquinavir impairs the invasion of cervical intraepithelial neoplasia cells via a reduction of MMP expression and activity. <i>Aids</i> , 2012, 26, 909-919.	2.2	33
43	A new antigen scanning strategy for monitoring HIV-1 specific T-cell immune responses. <i>Journal of Immunological Methods</i> , 2012, 375, 46-56.	1.4	11
44	Influence of MHC class I and II haplotypes on the experimental infection of Mauritian cynomolgus macaques with SHIV <sub>SF162P4cy</sub> . <i>Tissue Antigens</i> , 2012, 80, 36-45.	1.0	7
45	HIV-1 Tat Promotes Integrin-Mediated HIV Transmission to Dendritic Cells by Binding Env Spikes and Competes Neutralization by Anti-HIV Antibodies. <i>PLoS ONE</i> , 2012, 7, e48781.	2.5	56
46	Communication, recruitment and enrolment in the preventative and therapeutic phase I clinical trial against HIV/AIDS based on the recombinant HIV-1 Tat protein. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2011, 23, 939-946.	1.2	10
47	A combination HIV vaccine based on Tat and Env proteins was immunogenic and protected macaques from mucosal SHIV challenge in a pilot study. <i>Vaccine</i> , 2011, 29, 2918-2932.	3.8	20
48	Modulation of Th1/Th2 immune responses to HIV-1 Tat by new pro-GSH molecules. <i>Vaccine</i> , 2011, 29, 6823-6829.	3.8	26
49	Fibroblast Growth Factor-2 and the HIV-1 Tat Protein Synergize in Promoting Bcl-2 Expression and Preventing Endothelial Cell Apoptosis: Implications for the Pathogenesis of AIDS-Associated Kaposi's Sarcoma. <i>International Journal of Vascular Medicine</i> , 2011, 2011, 1-8.	1.0	12
50	Pharmacological management of Kaposi's sarcoma. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 1669-1690.	1.8	10
51	Human immunodeficiency virus protease inhibitors reduce the growth of human tumors <i>in vivo</i> a proteasome-independent block of angiogenesis and matrix metalloproteinases. <i>International Journal of Cancer</i> , 2011, 128, 82-93.	5.1	40
52	Global trends in molecular epidemiology of HIV-1 during 2000-2007. <i>Aids</i> , 2011, 25, 679-689.	2.2	602
53	Effect of the redox state on HIV-1 tat protein multimerization and cell internalization and trafficking. <i>Molecular and Cellular Biochemistry</i> , 2010, 345, 105-118.	3.1	15
54	Spindle cells from acquired immune deficiency syndrome-associated Kaposi's sarcoma lesions express telomerase activity directly relating to the RNA levels of fibroblast growth factor-2. <i>International Journal of Cancer</i> , 2010, 127, 2487-2489.	5.1	1

#	ARTICLE	IF	CITATIONS
55	Spindle cells from AIDS-associated Kaposi's sarcoma lesions express telomerase activity that is enhanced by Kaposi's sarcoma progression factors. <i>Oncology Reports</i> , 2010, 24, 219-23.	2.6	3
56	Therapeutic Immunization with HIV-1 Tat Reduces Immune Activation and Loss of Regulatory T-Cells and Improves Immune Function in Subjects on HAART. <i>PLoS ONE</i> , 2010, 5, e13540.	2.5	94
57	Impact of Viral Dose and Major Histocompatibility Complex Class IB Haplotype on Viral Outcome in Mauritian Cynomolgus Monkeys Vaccinated with Tat upon Challenge with Simian/Human Immunodeficiency Virus SHIV89.6P. <i>Journal of Virology</i> , 2010, 84, 8953-8958.	3.4	30
58	Characterization of HIV Type 1 Genetic Diversity Among South African Participants Enrolled in the AIDS Vaccine Integrated Project (AVIP) Study. <i>AIDS Research and Human Retroviruses</i> , 2010, 26, 705-709.	1.1	9
59	Identification of recent HIV infections and of factors associated with virus acquisition among pregnant women in 2004 and 2006 in Swaziland. <i>Journal of Clinical Virology</i> , 2010, 48, 180-183.	3.1	12
60	Fibroblast growth factor-2 transiently activates the p53 oncosuppressor protein in human primary vascular smooth muscle cells: Implications for atherogenesis. <i>Atherosclerosis</i> , 2010, 210, 400-406.	0.8	12
61	HIV-1 Tat-Based Vaccines: An Overview and Perspectives in the Field of HIV/AIDS Vaccine Development. <i>International Reviews of Immunology</i> , 2009, 28, 285-334.	3.3	38
62	Containment of Infection in Tat Vaccinated Monkeys After Rechallenge with a Higher Dose of SHIV89.6P<sub>cy243</sub>. <i>Viral Immunology</i> , 2009, 22, 117-124.	1.3	18
63	NKp44 expression, phylogenesis and function in non-human primate NK cells. <i>International Immunology</i> , 2009, 21, 245-255.	4.0	22
64	Contribution of Nonneutralizing Vaccine-Elicited Antibody Activities to Improved Protective Efficacy in Rhesus Macaques Immunized with Tat/Env Compared with Multigenic Vaccines. <i>Journal of Immunology</i> , 2009, 182, 3718-3727.	0.8	128
65	HIV-1 Tat Addresses Dendritic Cells to Induce a Predominant Th1-Type Adaptive Immune Response That Appears Prevalent in the Asymptomatic Stage of Infection. <i>Journal of Immunology</i> , 2009, 182, 2888-2897.	0.8	65
66	Immobilized HIV-1 Tat protein promotes gene transfer via a transactivation-independent mechanism which requires binding of Tat to viral particles. <i>Journal of Gene Medicine</i> , 2009, 11, 955-965.	2.8	26
67	Innovative Approaches to Develop Prophylactic and Therapeutic Vaccines against HIV/AIDS. <i>Advances in Experimental Medicine and Biology</i> , 2009, 655, 189-242.	1.6	13
68	Phase I therapeutic trial of the HIV-1 Tat protein and long term follow-up. <i>Vaccine</i> , 2009, 27, 3306-3312.	3.8	59
69	Induction of humoral and enhanced cellular immune responses by novel core-shell nanosphere- and microsphere-based vaccine formulations following systemic and mucosal administration. <i>Vaccine</i> , 2009, 27, 3605-3615.	3.8	39
70	Priming with a very low dose of DNA complexed with cationic block copolymers followed by protein boost elicits broad and long-lasting antigen-specific humoral and cellular responses in mice. <i>Vaccine</i> , 2009, 27, 4498-4507.	3.8	10
71	The preventive phase I trial with the HIV-1 Tat-based vaccine. <i>Vaccine</i> , 2009, 28, 371-378.	3.8	56
72	Clinical course of classic Kaposi's sarcoma in HIV-negative patients treated with the HIV protease inhibitor indinavir. <i>Aids</i> , 2009, 23, 534-538.	2.2	31

#	ARTICLE	IF	CITATIONS
73	Tat protein vaccination of cynomolgus macaques influences SHIV-89.6Pcy243 epitope variability. <i>Virus Genes</i> , 2008, 36, 105-115.	1.6	3
74	Viral outcome of simian human immunodeficiency virus SHIV-89.6P adapted to cynomolgus monkeys. <i>Archives of Virology</i> , 2008, 153, 463-472.	2.1	18
75	The Tat protein broadens T cell responses directed to the HIV-1 antigens Gag and Env: Implications for the design of new vaccination strategies against AIDS. <i>Vaccine</i> , 2008, 26, 727-737.	3.8	49
76	Characterization of immune responses elicited in mice by intranasal co-immunization with HIV-1 Tat, gp140 <sup>1-2</sup> V2Env and/or SIV Gag proteins and the nontoxicogenic heat-labile <i>Escherichia coli</i> enterotoxin. <i>Vaccine</i> , 2008, 26, 1214-1227.	3.8	20
77	Cross-clade immune responses to Gag p24 in patients infected with different HIV-1 subtypes and correlation with HLA class I and II alleles. <i>Vaccine</i> , 2008, 26, 5182-5187.	3.8	10
78	Comparative study of Tat vaccine regimens in Mauritian cynomolgus and Indian rhesus macaques: Influence of Mauritian MHC haplotypes on susceptibility/resistance to SHIV89.6P infection. <i>Vaccine</i> , 2008, 26, 3312-3321.	3.8	40
79	190 IRF-1 is required for full NF- $\kappa$ B transcriptional activity at the HIV-1 LTR enhancer. <i>Cytokine</i> , 2008, 43, 284.	3.2	0
80	Subtype Assignment and Phylogenetic Analysis of HIV Type 1 Strains in Patients from Swaziland. <i>AIDS Research and Human Retroviruses</i> , 2008, 24, 323-325.	1.1	3
81	The therapeutic phase I trial of the recombinant native HIV-1 Tat protein. <i>Aids</i> , 2008, 22, 2207-2209.	2.2	51
82	Primary Effusion Lymphoma Cells Undergoing Human Herpesvirus Type 8 Productive Infection Produce C-Type Retroviral Particles. <i>International Journal of Immunopathology and Pharmacology</i> , 2008, 21, 999-1006.	2.1	4
83	IRF-1 Is Required for Full NF- $\kappa$ B Transcriptional Activity at the Human Immunodeficiency Virus Type 1 Long Terminal Repeat Enhancer. <i>Journal of Virology</i> , 2008, 82, 3632-3641.	3.4	83
84	Functional Polymeric Nano/Microparticles for Surface Adsorption and Delivery of Protein and DNA Vaccines. <i>Current Drug Delivery</i> , 2008, 5, 230-242.	1.6	44
85	Problems and emerging approaches in HIV/AIDS vaccine development. <i>Expert Opinion on Emerging Drugs</i> , 2007, 12, 23-48.	2.4	31
86	A Replication-Competent Adenovirus-Human Immunodeficiency Virus (Ad-HIV) tat and Ad-HIV env Priming/Tat and Envelope Protein Boosting Regimen Elicits Enhanced Protective Efficacy against Simian/Human Immunodeficiency Virus SHIV 89.6P Challenge in Rhesus Macaques. <i>Journal of Virology</i> , 2007, 81, 3414-3427.	3.4	80
87	Candidate HIV-1 gp140 <sup>1-2</sup> V2, Gag and Tat vaccines protect against experimental HIV-1/MuLV challenge. <i>Vaccine</i> , 2007, 25, 6882-6890.	3.8	11
88	Multiprotein genetic vaccine in the SIV-Macaca animal model: a promising approach to generate sterilizing immunity to HIV infection. <i>Journal of Medical Primatology</i> , 2007, 36, 180-194.	0.6	17
89	Control of Human Herpes Virus Type 8-Associated Diseases by NK Cells. <i>Annals of the New York Academy of Sciences</i> , 2007, 1096, 37-43.	3.8	8
90	Preparation and Characterization of Innovative Protein-coated Poly(Methylmethacrylate) Core-shell Nanoparticles for Vaccine Purposes. <i>Pharmaceutical Research</i> , 2007, 24, 1870-1882.	3.5	34

#	ARTICLE	IF	CITATIONS
91	Evaluation of a Self-Inactivating Lentiviral Vector Expressing Simian Immunodeficiency Virus Gag for Induction of Specific Immune Responses <i>In Vitro</i> and <i>In Vivo</i> . <i>Viral Immunology</i> , 2006, 19, 690-701.	1.3	35
92	Non-neutralizing antibodies and vaccine-induced protection. <i>Retrovirology</i> , 2006, 3, S26.	2.0	6
93	Efficient systemic and mucosal responses against the HIV-1 Tat protein by prime/boost vaccination using the lipopeptide MALP-2 as adjuvant. <i>Vaccine</i> , 2006, 24, 2049-2056.	3.8	50
94	DNA prime and protein boost immunization with innovative polymeric cationic core-shell nanoparticles elicits broad immune responses and strongly enhance cellular responses of HIV-1 tat DNA vaccination. <i>Vaccine</i> , 2006, 24, 5655-5669.	3.8	46
95	Expression of human immunodeficiency virus type 1 tat from a replication-deficient herpes simplex type 1 vector induces antigen-specific T cell responses. <i>Vaccine</i> , 2006, 24, 7148-7158.	3.8	14
96	Intracellular HIV-1 Tat protein represses constitutive LMP2 transcription increasing proteasome activity by interfering with the binding of IRF-1 to STAT1. <i>Biochemical Journal</i> , 2006, 396, 371-380.	3.7	50
97	Immune response and protection by DNA vaccines expressing antigen 85B of <i>Mycobacterium tuberculosis</i> . <i>FEMS Microbiology Letters</i> , 2006, 262, 210-215.	1.8	9
98	Building collaborative networks for HIV/AIDS vaccine development: the AVIP experience. <i>Seminars in Immunopathology</i> , 2006, 28, 289-301.	4.0	6
99	Isolation and characterization of lymphatic microvascular endothelial cells from human tonsils. <i>Journal of Cellular Physiology</i> , 2006, 207, 107-113.	4.1	34
100	Candidate HIV-1 Tat vaccine development: from basic science to clinical trials. <i>Aids</i> , 2006, 20, 2245-2261.	2.2	61
101	Interleukin-2 continuous infusion and angiogenesis surrogate markers in metastatic renal cell carcinoma. <i>Annals of Oncology</i> , 2006, 17, 1335-1336.	1.2	0
102	A single administration of lentiviral vectors expressing either full-length human immunodeficiency virus 1 (HIV-1) HXB2 Rev/Env or codon-optimized HIV-1 JR-FL gp120 generates durable immune responses in mice. <i>Journal of General Virology</i> , 2006, 87, 1625-1634.	2.9	26
103	HIV-1 Tat Regulates Endothelial Cell Cycle Progression via Activation of the Ras/ERK MAPK Signaling Pathway. <i>Molecular Biology of the Cell</i> , 2006, 17, 1985-1994.	2.1	66
104	Innate anti-viral immunity is associated with the protection elicited by the simian immunodeficiency virus (SIV) live attenuated virus vaccine in cynomolgus monkeys. <i>Medical Science Monitor</i> , 2006, 12, BR330-40.	1.1	9
105	The use of HAART for biological tumour therapy. <i>Journal of HIV Therapy</i> , 2006, 11, 53-6.	0.6	6
106	Vaccines based on the native HIV Tat protein and on the combination of Tat and the structural HIV protein variant I <sup>2</sup> V2 Env. <i>Microbes and Infection</i> , 2005, 7, 1392-1399.	1.9	17
107	Criteria for selection of HIV vaccine candidates – general principles. <i>Microbes and Infection</i> , 2005, 7, 1433-1435.	1.9	11
108	Rational vaccine strategies against AIDS: background and rationale. <i>Microbes and Infection</i> , 2005, 7, 1445-1452.	1.9	9

#	ARTICLE	IF	CITATIONS
109	Downregulation of the major histocompatibility complex class I molecules by human herpesvirus type 8 and impaired natural killer cell activity in primary effusion lymphoma development. <i>British Journal of Haematology</i> , 2005, 130, 92-95.	2.5	11
110	Enhanced cellular immunity to SIV Gag following co-administration of adenoviruses encoding wild-type or mutant HIV Tat and SIV Gag. <i>Virology</i> , 2005, 342, 1-12.	2.4	24
111	Molecular and Functional Characterization of NKG2D, NKp80, and NKG2C Triggering NK Cell Receptors in Rhesus and Cynomolgus Macaques: Monitoring of NK Cell Function during Simian HIV Infection. <i>Journal of Immunology</i> , 2005, 174, 5695-5705.	0.8	41
112	The Presence of Anti-Tat Antibodies Is Predictive of Long-Term Nonprogression to AIDS or Severe Immunodeficiency: Findings in a Cohort of HIV-1 Seroconverters. <i>Journal of Infectious Diseases</i> , 2005, 191, 1321-1324.	4.0	118
113	P-451 HIV-protease inhibitors as antitumoral therapy in advanced NSCLC patients. <i>Lung Cancer</i> , 2005, 49, S235.	2.0	0
114	Core-shell microspheres by dispersion polymerization as promising delivery systems for proteins. <i>Journal of Biomaterials Science, Polymer Edition</i> , 2005, 16, 1557-1574.	3.5	23
115	Infection of a Simian B Cell Line by Human and Simian Immunodeficiency Viruses. <i>AIDS Research and Human Retroviruses</i> , 2004, 20, 723-732.	1.1	4
116	Qualitative T-Helper Responses to Multiple Viral Antigens Correlate with Vaccine-Induced Immunity to Simian/Human Immunodeficiency Virus Infection. <i>Journal of Virology</i> , 2004, 78, 3333-3342.	3.4	49
117	Recent Advances in the Development of HIV-1 Tat-Based Vaccines. <i>Current HIV Research</i> , 2004, 2, 357-376.	0.5	39
118	HIV-1 Tat Protein Modulates the Generation of Cytotoxic T Cell Epitopes by Modifying Proteasome Composition and Enzymatic Activity. <i>Journal of Immunology</i> , 2004, 173, 3838-3843.	0.8	101
119	Antitumour effects of antiretroviral therapy. <i>Nature Reviews Cancer</i> , 2004, 4, 861-875.	28.4	95
120	HIV-Tat down-regulates telomerase activity in the nucleus of human CD4+ T cells. <i>Cell Death and Differentiation</i> , 2004, 11, 782-784.	11.2	12
121	Use of retroviral vectors for the analysis of SIV/HIV-specific CD8 T cell responses. <i>Journal of Immunological Methods</i> , 2004, 291, 153-163.	1.4	6
122	Circular viral DNA detection and junction sequence analysis from PBMC of SHIV-infected cynomolgus monkeys with undetectable virus plasma RNA. <i>Virology</i> , 2004, 324, 531-539.	2.4	12
123	Analysis of the Signal Transduction Pathway Leading to Human Immunodeficiency Virus-1-Induced Interferon Regulatory Factor-1 Upregulation. <i>Annals of the New York Academy of Sciences</i> , 2004, 1030, 187-195.	3.8	11
124	Nonstructural HIV proteins as targets for prophylactic or therapeutic vaccines. <i>Current Opinion in Biotechnology</i> , 2004, 15, 543-556.	6.6	32
125	Novel biocompatible anionic polymeric microspheres for the delivery of the HIV-1 Tat protein for vaccine application. <i>Vaccine</i> , 2004, 22, 2910-2924.	3.8	39
126	Long-term protection against SHIV89.6P replication in HIV-1 Tat vaccinated cynomolgus monkeys. <i>Vaccine</i> , 2004, 22, 3258-3269.	3.8	70

#	ARTICLE	IF	CITATIONS
127	On the Role of Interferon Regulatory Factors in HIV-1 Replication. <i>Annals of the New York Academy of Sciences</i> , 2003, 1010, 29-42.	3.8	16
128	Efficient mucosal delivery of the HIV-1 Tat protein using the synthetic lipopeptide MALP-2 as adjuvant. <i>European Journal of Immunology</i> , 2003, 33, 1548-1556.	2.9	64
129	SHIV89.6P pathogenicity in cynomolgus monkeys and control of viral replication and disease onset by human immunodeficiency virus type 1 Tat vaccine. <i>Journal of Medical Primatology</i> , 2003, 29, 193-208.	0.6	51
130	HIV protease inhibitors as new treatment options for Kaposi's sarcoma. <i>Drug Resistance Updates</i> , 2003, 6, 173-181.	14.4	13
131	Immunization with low doses of HIV-1 tat DNA delivered by novel cationic block copolymers induces CTL responses against Tat. <i>Vaccine</i> , 2003, 21, 1103-1111.	3.8	27
132	Red blood cell-mediated delivery of recombinant HIV-1 Tat protein in mice induces anti-Tat neutralizing antibodies and CTL. <i>Vaccine</i> , 2003, 21, 2073-2081.	3.8	40
133	Mucosal delivery of the human immunodeficiency virus-1 Tat protein in mice elicits systemic neutralizing antibodies, cytotoxic T lymphocytes and mucosal IgA. <i>Vaccine</i> , 2003, 21, 3972-3981.	3.8	28
134	Use of HIV protease inhibitors to block Kaposi's sarcoma and tumour growth. <i>Lancet Oncology</i> , The, 2003, 4, 537-547.	10.7	125
135	CD8+CD28-T Lymphocytes from HIV-1-Infected Patients Secrete Factors That Induce Endothelial Cell Proliferation and Acquisition of Kaposi's Sarcoma Cell Features. <i>Journal of Interferon and Cytokine Research</i> , 2003, 23, 523-531.	1.2	9
136	Sequence Conservation and Antibody Cross-Recognition of Clade B Human Immunodeficiency Virus (HIV) Type 1 Tat Protein in HIV-1-Infected Italians, Ugandans, and South Africans. <i>Journal of Infectious Diseases</i> , 2003, 188, 1171-1180.	4.0	75
137	Human CD38 interferes with HIV-1 fusion through a sequence homologous to the V3 loop of the viral envelope glycoprotein gp120. <i>FASEB Journal</i> , 2003, 17, 1-20.	0.5	28
138	HIV protease inhibitors: antiretroviral agents with anti-inflammatory, anti-angiogenic and anti-tumour activity. <i>Journal of Antimicrobial Chemotherapy</i> , 2003, 51, 207-211.	3.0	28
139	HIV-1 Tat-Based Vaccines: From Basic Science to Clinical Trials. <i>DNA and Cell Biology</i> , 2002, 21, 599-610.	1.9	35
140	Review: IRF Regulation of HIV-1 Long Terminal Repeat Activity. <i>Journal of Interferon and Cytokine Research</i> , 2002, 22, 27-37.	1.2	43
141	Calibrated Real-Time PCR Assay for Quantitation of Human Herpesvirus 8 DNA in Biological Fluids. <i>Journal of Clinical Microbiology</i> , 2002, 40, 4652-4658.	3.9	45
142	Modulation of Human Immunodeficiency Virus 1 Replication by Interferon Regulatory Factors. <i>Journal of Experimental Medicine</i> , 2002, 195, 1359-1370.	8.5	102
143	Angiogenic Effects of Extracellular Human Immunodeficiency Virus Type 1 Tat Protein and Its Role in the Pathogenesis of AIDS-Associated Kaposi's Sarcoma. <i>Clinical Microbiology Reviews</i> , 2002, 15, 310-326.	13.6	115
144	Native HIV-1 Tat Protein Targets Monocyte-Derived Dendritic Cells and Enhances Their Maturation, Function, and Antigen-Specific T Cell Responses. <i>Journal of Immunology</i> , 2002, 168, 197-206.	0.8	158

#	ARTICLE	IF	CITATIONS
145	Treatment of Kaposi's sarcoma—an update. <i>Anti-Cancer Drugs</i> , 2002, 13, 977-987.	1.4	24
146	Guanylate-Binding Protein-1 Expression Is Selectively Induced by Inflammatory Cytokines and Is an Activation Marker of Endothelial Cells during Inflammatory Diseases. <i>American Journal of Pathology</i> , 2002, 161, 1749-1759.	3.8	129
147	Micellar-type complexes of tailor-made synthetic block copolymers containing the HIV-1 tat DNA for vaccine application. <i>Vaccine</i> , 2002, 20, 2303-2317.	3.8	28
148	NK cell activity controls human herpesvirus 8 latent infection and is restored upon highly active antiretroviral therapy in AIDS patients with regressing Kaposi's sarcoma. <i>European Journal of Immunology</i> , 2002, 32, 2711-2720.	2.9	84
149	The Mycoplasma-derived lipopeptide MALP-2 is a potent mucosal adjuvant. <i>European Journal of Immunology</i> , 2002, 32, 2857-2865.	2.9	113
150	Identification of cytotoxic T lymphocyte epitopes of human herpesvirus 8. <i>Immunology</i> , 2002, 106, 395-403.	4.4	45
151	HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi sarcoma. <i>Nature Medicine</i> , 2002, 8, 225-232.	30.7	299
152	Inflammatory cytokines stimulate vascular smooth muscle cells locomotion and growth by enhancing $\alpha 5 \beta 1$ integrin expression and function. <i>Atherosclerosis</i> , 2001, 154, 377-385.	0.8	68
153	Vaccination with DNA containing tat coding sequences and unmethylated CpG motifs protects cynomolgus monkeys upon infection with simian/human immunodeficiency virus (SHIV89.6P). <i>Vaccine</i> , 2001, 19, 2862-2877.	3.8	135
154	Characterization of HIV-1 Tat proteins mutated in the transactivation domain for prophylactic and therapeutic application. <i>Vaccine</i> , 2001, 19, 3408-3419.	3.8	16
155	HIV-1 Tat vaccines. <i>Virus Research</i> , 2001, 82, 91-101.	2.2	21
156	Interactions between endothelial cells and HIV-1. <i>International Journal of Biochemistry and Cell Biology</i> , 2001, 33, 371-390.	2.8	59
157	Biology of Kaposi's sarcoma. <i>European Journal of Cancer</i> , 2001, 37, 1251-1269.	2.8	228
158	NOVEL STRATEGIES TOWARD THE DEVELOPMENT OF AN EFFECTIVE VACCINE TO PREVENT HUMAN IMMUNODEFICIENCY VIRUS INFECTION OR ACQUIRED IMMUNODEFICIENCY VIRUS*. <i>Clinical Research and Regulatory Affairs</i> , 2001, 18, 293-327.	2.1	1
159	Complex associates of plasmid DNA and a novel class of block copolymers with PEG and cationic segments as new vectors for gene delivery. <i>Journal of Biomaterials Science, Polymer Edition</i> , 2001, 12, 209-228.	3.5	19
160	Human Herpesvirus-8 and Other Viral Infections, Papua New Guinea. <i>Emerging Infectious Diseases</i> , 2001, 7, 893-895.	4.3	29
161	Human herpesvirus-8 and Kaposi's sarcoma: Relationship with the multistep concept of tumorigenesis. <i>Advances in Cancer Research</i> , 2001, 81, 125-159.	5.0	69
162	Reactivation and role of HHV-8 in Kaposi's sarcoma initiation. <i>Advances in Cancer Research</i> , 2001, 81, 161-200.	5.0	72

#	ARTICLE	IF	CITATIONS
163	Comparison of early plasma RNA loads in different macaque species and the impact of different routes of exposure on SIV/SHIV infection. <i>Journal of Medical Primatology</i> , 2001, 30, 207-214.	0.6	39
164	Kaposi's sarcoma-associated herpesvirus serology in Europe and Uuganda: Multicentre study with multiple and novel assays. <i>Journal of Medical Virology</i> , 2001, 65, 123-132.	5.0	56
165	Identification, molecular cloning and functional characterization of NKp46 and NKp30 natural cytotoxicity receptors in <i>Macaca fascicularis</i> NK cells. <i>European Journal of Immunology</i> , 2001, 31, 3546-3556.	2.9	60
166	A seroprevalence study of human herpesvirus type 8 (HHV8) in eastern and Central Africa and in the Mediterranean area. <i>European Journal of Epidemiology</i> , 2001, 17, 871-876.	5.7	47
167	Prevalence, Incidence and Correlates of HHV-8/KSHV Infection and Kaposi's Sarcoma in Renal and Liver Transplant Recipients. <i>Journal of Infection</i> , 2001, 43, 195-199.	3.3	97
168	The helical domain of GBP-1 mediates the inhibition of endothelial cell proliferation by inflammatory cytokines. <i>EMBO Journal</i> , 2001, 20, 5568-5577.	7.8	166
169	Activation of Matrix-Metalloproteinase-2 and Membrane-Type-1-Matrix-Metalloproteinase in Endothelial Cells and Induction of Vascular Permeability In Vivo by Human Immunodeficiency Virus-1 Tat Protein and Basic Fibroblast Growth Factor. <i>Molecular Biology of the Cell</i> , 2001, 12, 2934-2946.	2.1	110
170	Transcription Pattern of Human Herpesvirus 8 Open Reading Frame K3 in Primary Effusion Lymphoma and Kaposi's Sarcoma. <i>Journal of Virology</i> , 2001, 75, 7161-7174.	3.4	34
171	Clearance of Human Herpesvirus 8 from Blood and Regression of Leukopenia-Associated Aggressive Classic Kaposi's Sarcoma during Interferon- $\alpha$ Therapy: A Case Report. <i>Clinical Infectious Diseases</i> , 2001, 33, 1782-1785.	5.8	7
172	Serum Concentrations of Fibroblast Growth Factor 2 Are Increased in HIV Type 1-Infected Patients and Inversely Related to Survival Probability. <i>AIDS Research and Human Retroviruses</i> , 2001, 17, 1035-1039.	1.1	22
173	Kaposi's sarcoma-associated herpesvirus serology in Europe and Uuganda: Multicentre study with multiple and novel assays. <i>Journal of Medical Virology</i> , 2001, 65, 123-132.	5.0	3
174	Incidence of Kaposi's sarcoma and HHV-8 seroprevalence among homosexual men with known dates of HIV seroconversion. <i>Aids</i> , 2000, 14, 1647-1653.	2.2	28
175	Cytokine-mediated growth promotion of Kaposi's sarcoma and primary effusion lymphoma. <i>Seminars in Cancer Biology</i> , 2000, 10, 367-381.	9.6	71
176	Limited expression of R5-tropic HIV-1 in CCR5-positive type 1 "polarized T cells explained by their ability to produce RANTES, MIP-1 $\alpha$ , and MIP-1 $\beta$ . <i>Blood</i> , 2000, 95, 1167-1174.	1.4	47
177	Lytic Growth of Human Herpesvirus 8: Morphological Aspects. <i>Ultrastructural Pathology</i> , 2000, 24, 301-310.	0.9	5
178	Prevalence and Risk Factors for Human Herpesvirus 8 Infection in Northern Cameroon. <i>Sexually Transmitted Diseases</i> , 2000, 27, 159-164.	1.7	51
179	CD4-Independent Infection of Two CD4 $^{+}$ /CCR5 $^{+}$ /CXCR4 $^{+}$ Pre-T-Cell Lines by Human and Simian Immunodeficiency Viruses. <i>Journal of Virology</i> , 2000, 74, 6689-6694.	3.4	19
180	Mechanism of Paclitaxel Activity in Kaposi's Sarcoma. <i>Journal of Immunology</i> , 2000, 165, 509-517.	0.8	75

#	ARTICLE	IF	CITATIONS
181	High Seroprevalence of Antibodies to Human Herpesvirus-8 in Egyptian Children: Evidence of Nonsexual Transmission. <i>Journal of the National Cancer Institute</i> , 1999, 91, 465-469.	6.3	139
182	Expression of K13/v-FLIP Gene of Human Herpesvirus 8 and Apoptosis in Kaposi's Sarcoma Spindle Cells. <i>Journal of the National Cancer Institute</i> , 1999, 91, 1725-1733.	6.3	156
183	Human Herpesvirus 8 Seropositivity and Risk of Kaposi's Sarcoma and Other Acquired Immunodeficiency Syndrome-Related Diseases. <i>Journal of the National Cancer Institute</i> , 1999, 91, 1468-1474.	6.3	130
184	Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine. <i>Nature Medicine</i> , 1999, 5, 643-650.	30.7	288
185	Human herpesvirus-8 (HHV-8) gene expression in Kaposi's sarcoma (KS) primary lesions: an in situ hybridization study. <i>Leukemia</i> , 1999, 13, S110-S112.	7.2	37
186	HHV-8 and multistep tumorigenesis. <i>Trends in Microbiology</i> , 1999, 7, 310-311.	7.7	6
187	Expression of human herpesvirus-8 (HHV-8) encoded pathogenic genes in Kaposi's Sarcoma (KS) primary lesions. <i>Advances in Enzyme Regulation</i> , 1999, 39, 331-339.	2.6	17
188	Variability and evolution of Kaposi's sarcoma-associated herpesvirus in Europe and Africa. <i>Aids</i> , 1999, 13, 1165-1176.	2.2	107
189	Alpha Interferon Inhibits Human Herpesvirus 8 (HHV-8) Reactivation in Primary Effusion Lymphoma Cells and Reduces HHV-8 Load in Cultured Peripheral Blood Mononuclear Cells. <i>Journal of Virology</i> , 1999, 73, 4029-4041.	3.4	70
190	Prevalence and determinants of anti-lytic and anti-latent antibodies to human herpesvirus-8 among Italian individuals at risk of sexually and parenterally transmitted infections. , 1998, 77, 361-365.		89
191	Basic fibroblast growth factor supports human olfactory neurogenesis by autocrine/paracrine mechanisms. <i>Neuroscience</i> , 1998, 86, 881-893.	2.3	33
192	Kaposi's sarcoma: a result of the interplay among inflammatory cytokines, angiogenic factors and viral agents. <i>Cytokine and Growth Factor Reviews</i> , 1998, 9, 63-83.	7.2	173
193	Inflammatory cytokines induce the expression of basic fibroblast growth factor (bFGF) isoforms required for the growth of Kaposi's sarcoma and endothelial cells through the activation of AP-1 response elements in the bFGF promoter. <i>Aids</i> , 1998, 12, 19-27.	2.2	63
194	Kaposi sarcoma-associated herpesvirus/human herpesvirus 8, cytokines, growth factors and HIV in pathogenesis of Kaposi's sarcoma. <i>Current Opinion in Infectious Diseases</i> , 1998, 11, 97-106.	3.1	22
195	Purified Tat induces inflammatory response genes in Kaposi's sarcoma cells. <i>Aids</i> , 1998, 12, 1753-1761.	2.2	28
196	Î³-Interferon Production in Peripheral Blood Mononuclear Cells and Tumor Infiltrating Lymphocytes From Kaposi's Sarcoma Patients: Correlation With the Presence of Human Herpesvirus-8 in Peripheral Blood Mononuclear Cells and Lesional Macrophages. <i>Blood</i> , 1998, 91, 968-976.	1.4	104
197	Î³-Interferon Production in Peripheral Blood Mononuclear Cells and Tumor Infiltrating Lymphocytes From Kaposi's Sarcoma Patients: Correlation With the Presence of Human Herpesvirus-8 in Peripheral Blood Mononuclear Cells and Lesional Macrophages. <i>Blood</i> , 1998, 91, 968-976.	1.4	3
198	Kaposi's Sarcoma Pathogenesis: A Link between Immunology and Tumor Biology. <i>Critical Reviews in Oncogenesis</i> , 1998, 9, 107-124.	0.4	43

#	ARTICLE	IF	CITATIONS
199	HIV-1 Tat protein exits from cells via a leaderless secretory pathway and binds to extracellular matrix-associated heparan sulfate proteoglycans through its basic region. <i>Aids</i> , 1997, 11, 1421-1431.	2.2	412
200	Circulating spindle cells: correlation with human herpesvirus-8 (HHV-8) infection and Kaposi's sarcoma. <i>Lancet, The</i> , 1997, 349, 255.	13.7	50
201	ISOLATION OF HUMAN HERPESVIRUS-8 (HHV-8) FROM PBMC OF AIDS-KS PATIENTS AND VIRAL TRANSMISSION TO PRIMARY CELL CULTURE. <i>Journal of Acquired Immune Deficiency Syndromes</i> , 1997, 14, A34.	0.3	0
202	Differential activation of the extracellular signal-regulated kinase, Jun Kinase and Janus Kinase-Stat pathways by oncostatin M and basic fibroblast growth factor in AIDS-derived Kaposi's sarcoma cells. <i>Aids</i> , 1996, 10, 369-378.	2.2	35
203	Block of Tat-Mediated Transactivation of Tumor Necrosis Factor $\beta$ Gene Expression by Polymeric-TAR Decoys. <i>Virology</i> , 1996, 222, 252-256.	2.4	15
204	Efficacy of antitumor Gene Therapy in the Presence of High Multiplicity Infection and Inflammatory Cytokines. <i>Human Gene Therapy</i> , 1996, 7, 2209-2216.	2.7	6
205	Angiogenic properties of human immunodeficiency virus type 1 Tat protein.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1995, 92, 4838-4842.	7.1	209
206	Regulation of cellular gene expression and function by the human immunodeficiency virus type 1 tat protein. <i>Journal of Biomedical Science</i> , 1995, 2, 189-202.	7.0	82
207	HIV-1 Infection of Primary Human Neuroblasts. <i>Virology</i> , 1995, 210, 221-225.	2.4	43
208	Cytokines from activated T cells induce normal endothelial cells to acquire the phenotypic and functional features of AIDS-Kaposi's sarcoma spindle cells.. <i>Journal of Clinical Investigation</i> , 1995, 95, 1723-1734.	8.2	150
209	Kaposi's Sarcoma, Vascular Permeability, and Scientific Integrity. <i>JAMA - Journal of the American Medical Association</i> , 1994, 272, 918.	7.4	0
210	HIV-1 Gene Expression and Replication in Neuronal and Glial Cell Lines with Immature Phenotype: Effects of Nerve Growth Factor. <i>Virology</i> , 1994, 200, 668-676.	2.4	30
211	Synergy between basic fibroblast growth factor and HIV-1 Tat protein in induction of Kaposi's sarcoma. <i>Nature</i> , 1994, 371, 674-680.	27.8	592
212	Inhibition of Human Immunodeficiency Virus Type-1 by Retroviral Vectors Expressing Antisense-TAR. <i>Human Gene Therapy</i> , 1994, 5, 1467-1475.	2.7	41
213	Block of AIDS-Kaposi's sarcoma (KS) cell growth, angiogenesis, and lesion formation in nude mice by antisense oligonucleotide targeting basic fibroblast growth factor. A novel strategy for the therapy of KS.. <i>Journal of Clinical Investigation</i> , 1994, 94, 1736-1746.	8.2	125
214	The Tat protein of human immunodeficiency virus type 1, a growth factor for AIDS Kaposi sarcoma and cytokine-activated vascular cells, induces adhesion of the same cell types by using integrin receptors recognizing the RGD amino acid sequence.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1993, 90, 7941-7945.	7.1	333
215	Cytokines and Growth Factors in the Pathogenesis of AIDS-Associated Kaposi's Sarcoma. <i>Immunological Reviews</i> , 1992, 127, 147-155.	6.0	148
216	Pathogenesis of AIDS-Associated Kaposi's Sarcoma. <i>Hematology/Oncology Clinics of North America</i> , 1991, 5, 281-295.	2.2	91

#	ARTICLE	IF	CITATIONS
217	Molecular Mechanisms in the Pathogenesis of AIDS-Associated Kaposi's Sarcoma. <i>Advances in Experimental Medicine and Biology</i> , 1991, 303, 27-38.	1.6	24
218	Tat protein of HIV-1 stimulates growth of cells derived from Kaposi's sarcoma lesions of AIDS patients. <i>Nature</i> , 1990, 345, 84-86.	27.8	921
219	Kaposi's sarcoma and AIDS. <i>Nature</i> , 1990, 346, 801-802.	27.8	4
220	In Reply: Pseudotypes in HIV-Infected Mice. <i>Science</i> , 1990, 250, 1153-1154.	12.6	1
221	Expanded HIV-1 cellular tropism by phenotypic mixing with murine endogenous retroviruses. <i>Science</i> , 1990, 247, 848-852.	12.6	175
222	AIDS-Kaposi's sarcoma-derived cells express cytokines with autocrine and paracrine growth effects. <i>Science</i> , 1989, 243, 223-226.	12.6	464
223	Productive dual infection of human CD4+ T lymphocytes by HIV-1 and HHV-6. <i>Nature</i> , 1989, 337, 370-373.	27.8	354
224	Biologically diverse molecular variants within a single HIV-1 isolate. <i>Nature</i> , 1988, 334, 444-447.	27.8	309
225	Kaposi's sarcoma cells: long-term culture with growth factor from retrovirus-infected CD4+ T cells. <i>Science</i> , 1988, 242, 426-430.	12.6	353
226	The sor gene of HIV-1 is required for efficient virus transmission in vitro. <i>Science</i> , 1987, 237, 888-893.	12.6	408
227	Clinical and immunological findings in four infants with Omenn's syndrome: A form of severe combined immunodeficiency with phenotypically normal T cells, elevated IgE, and eosinophilia. <i>Clinical Immunology and Immunopathology</i> , 1987, 44, 123-133.	2.0	30
228	New human and simian HIV-related retroviruses possess functional transactivator (tat) gene. <i>Nature</i> , 1987, 328, 548-550.	27.8	101
229	Results in two infants with the DiGeorge syndrome—Effects of long-term TP5. <i>Clinical Immunology and Immunopathology</i> , 1986, 39, 222-230.	2.0	8
230	HIV-1 therapeutic vaccines in clinical development to intensify or replace antiretroviral therapy: the promising results of the Tat vaccine. <i>Expert Review of Vaccines</i> , 0, , 1-11.	4.4	1